[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @crashkolnikov Notes From TBC Regeneron ($regn) has been making significant progress with its pipeline, including the successful phase III trial of garetosmab and the potential for a long-acting version of its Dupixent replacement. The company's CEO has been engaging in discussions with investors, providing insights into its strategy and pipeline. Additionally, Regeneron's partnership with Mammoth Biosciences to develop next-gen CRISPR therapies has been highlighted as a promising development. ### Engagements: XXX [#](/creator/twitter::1879800680577163264/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +18% - X Months XXXXXXX +246% ### Mentions: X [#](/creator/twitter::1879800680577163264/posts_active)  - X Week XX +35% - X Month XX -XX% - X Months XXX +126% ### Followers: XXX [#](/creator/twitter::1879800680577163264/followers)  - X Week XXX +0.72% - X Month XXX +6.90% - X Months XXX +224% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1879800680577163264/influencer_rank)  ### Social Influence [#](/creator/twitter::1879800680577163264/influence) --- **Social category influence** [stocks](/list/stocks) XXXXX% [luxury brands](/list/luxury-brands) XXXX% [automotive brands](/list/automotive-brands) XXXX% [finance](/list/finance) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [$regn](/topic/$regn) #20, [$brkr](/topic/$brkr) #9, [ptc inc](/topic/ptc-inc) 1.35%, [$ptc](/topic/$ptc) 1.35%, [$105share](/topic/$105share) 1.35%, [$tmo](/topic/$tmo) 1.35%, [regeneron pharmaceuticals inc](/topic/regeneron-pharmaceuticals-inc) #20, [bruker corp](/topic/bruker-corp) #10, [6 months](/topic/6-months) 1.35%, [deep dive](/topic/deep-dive) XXXX% **Top accounts mentioned or mentioned by** [@tofdaj](/creator/undefined) [@paulbiogeek](/creator/undefined) [@jeremie0117](/creator/undefined) [@evfcfaddict](/creator/undefined) [@clarksquarecap](/creator/undefined) [@johnhempton](/creator/undefined) [@bruker](/creator/undefined) [@longequity](/creator/undefined) [@renesellmann](/creator/undefined) [@biotechobserver](/creator/undefined) [@biotechvantage](/creator/undefined) [@metacriticcap](/creator/undefined) [@amir](/creator/undefined) [@grok](/creator/undefined) **Top assets mentioned** [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Bruker, Corp. (BRKR)](/topic/$brkr) [PTC Inc (PTC)](/topic/ptc-inc) [Thermo Fisher Scientific Inc. (TMO)](/topic/$tmo) [Microsoft Corp. (MSFT)](/topic/microsoft) ### Top Social Posts [#](/creator/twitter::1879800680577163264/posts) --- Top posts by engagements in the last XX hours "New two-parter on $PTC. In Part X we'll take a look at PTC's strategy and its various growth levers as well as context around how PTC arrived at its current position. In Part X we'll go deeper into products" [X Link](https://x.com/crashkolnikov/status/1971585829979165071) [@crashkolnikov](/creator/x/crashkolnikov) 2025-09-26T14:41Z XXX followers, XXX engagements "New $BRKR pitch from @jeremie0117" [X Link](https://x.com/crashkolnikov/status/1978359905170972833) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-15T07:18Z XXX followers, XXX engagements "$BRKR getting material NMR orders from US universities again" [X Link](https://x.com/crashkolnikov/status/1974074735379271907) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-03T11:31Z XXX followers, XXX engagements ""Why Regeneron is giving away sequencing for free" (answer: for access to the data) $REGN" [X Link](https://x.com/crashkolnikov/status/1974130814012305444) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-03T15:13Z XXX followers, 1080 engagements "$REGN planning DB-OTO US regulatory submission this year" [X Link](https://x.com/crashkolnikov/status/1977387833766629416) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-12T14:56Z XXX followers, 2060 engagements "@jeremie0117 And dont forget to check out my $BRKR deep dive if you havent yet. I posted X months too early but still excited about it Theres a paywall now but newbies can still cash in a voucher to read for free" [X Link](https://x.com/crashkolnikov/status/1978360203008450648) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-15T07:20Z XXX followers, XXX engagements "New $REGN post looking at the possibility of a coming franchise in hearing loss - a massive area of unmet need. News this week indicates REGN is moving quickly to regulatory submission in the first of numerous genetic targets" [X Link](https://x.com/crashkolnikov/status/1978459932732080613) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-15T13:56Z XXX followers, 1207 engagements "@BiotechVantage What am I missing about cemdisiran +/- pozelimab It seems to be one of $REGN 's potential sleeper assets that no one seems to care about. gMG PNH GA. + they've told us recently additional indications are coming" [X Link](https://x.com/crashkolnikov/status/1960338247973781671) [@crashkolnikov](/creator/x/crashkolnikov) 2025-08-26T13:47Z XXX followers, XXX engagements "The Rolls of Rolls-Royce talking about BEVs in 1900: They are perfectly noiseless and clean. There is no smell or vibration and they should become very useful for town use when fixed charging stations can be arranged. But for country use I do not anticipate they will be very serviceable - at least for many years to come" [X Link](https://x.com/crashkolnikov/status/1977693815927349329) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-13T11:12Z XXX followers, XXX engagements "Looks like DB-OTO could be the leading contender for the first "not invented here" approval at $REGN. The other is cemdisiran but it's filing later without FTD. DB-OTO could be approval no. XX or XX depending whether garetosmab gets there first" [X Link](https://x.com/crashkolnikov/status/1977749161035301202) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-13T14:51Z XXX followers, 1065 engagements "DB-OTO awarded National Priority Voucher meaning decision within 1-2 months of filing. Having only entered trials in mid-23 it could be on the market XXX years later if approved What else has moved that fast outside Operation Warp Speed $REGN" [X Link](https://x.com/crashkolnikov/status/1979112539230274016) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-17T09:09Z XXX followers, XXX engagements "Were hearing the company may make it available either at an extremely low price or for free which of course is part of a national priority to make drugs more affordable so we would love that Sounds like $REGN might not be planning to make any money on DB-OTO. But as I point out above there's a lot more coming from them in this field - next up is GJB2 which is much less rare" [X Link](https://x.com/crashkolnikov/status/1979114370295578726) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-17T09:16Z XXX followers, XXX engagements "@MetacriticCap @amir Like Intel handed the Apple business to TSMC Microsoft hands the OpenAI business to Oracle" [X Link](https://x.com/crashkolnikov/status/1979288417092669566) [@crashkolnikov](/creator/x/crashkolnikov) 2025-10-17T20:48Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@crashkolnikov Notes From TBC
Regeneron ($regn) has been making significant progress with its pipeline, including the successful phase III trial of garetosmab and the potential for a long-acting version of its Dupixent replacement. The company's CEO has been engaging in discussions with investors, providing insights into its strategy and pipeline. Additionally, Regeneron's partnership with Mammoth Biosciences to develop next-gen CRISPR therapies has been highlighted as a promising development.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX +18%
- X Months XXXXXXX +246%
Mentions: X #
- X Week XX +35%
- X Month XX -XX%
- X Months XXX +126%
Followers: XXX #
- X Week XXX +0.72%
- X Month XXX +6.90%
- X Months XXX +224%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXXX% luxury brands XXXX% automotive brands XXXX% finance XXXX% technology brands XXXX%
Social topic influence $regn #20, $brkr #9, ptc inc 1.35%, $ptc 1.35%, $105share 1.35%, $tmo 1.35%, regeneron pharmaceuticals inc #20, bruker corp #10, 6 months 1.35%, deep dive XXXX%
Top accounts mentioned or mentioned by @tofdaj @paulbiogeek @jeremie0117 @evfcfaddict @clarksquarecap @johnhempton @bruker @longequity @renesellmann @biotechobserver @biotechvantage @metacriticcap @amir @grok
Top assets mentioned Regeneron Pharmaceuticals Inc (REGN) Bruker, Corp. (BRKR) PTC Inc (PTC) Thermo Fisher Scientific Inc. (TMO) Microsoft Corp. (MSFT)
Top Social Posts #
Top posts by engagements in the last XX hours
"New two-parter on $PTC. In Part X we'll take a look at PTC's strategy and its various growth levers as well as context around how PTC arrived at its current position. In Part X we'll go deeper into products"
X Link @crashkolnikov 2025-09-26T14:41Z XXX followers, XXX engagements
"New $BRKR pitch from @jeremie0117"
X Link @crashkolnikov 2025-10-15T07:18Z XXX followers, XXX engagements
"$BRKR getting material NMR orders from US universities again"
X Link @crashkolnikov 2025-10-03T11:31Z XXX followers, XXX engagements
""Why Regeneron is giving away sequencing for free" (answer: for access to the data) $REGN"
X Link @crashkolnikov 2025-10-03T15:13Z XXX followers, 1080 engagements
"$REGN planning DB-OTO US regulatory submission this year"
X Link @crashkolnikov 2025-10-12T14:56Z XXX followers, 2060 engagements
"@jeremie0117 And dont forget to check out my $BRKR deep dive if you havent yet. I posted X months too early but still excited about it Theres a paywall now but newbies can still cash in a voucher to read for free"
X Link @crashkolnikov 2025-10-15T07:20Z XXX followers, XXX engagements
"New $REGN post looking at the possibility of a coming franchise in hearing loss - a massive area of unmet need. News this week indicates REGN is moving quickly to regulatory submission in the first of numerous genetic targets"
X Link @crashkolnikov 2025-10-15T13:56Z XXX followers, 1207 engagements
"@BiotechVantage What am I missing about cemdisiran +/- pozelimab It seems to be one of $REGN 's potential sleeper assets that no one seems to care about. gMG PNH GA. + they've told us recently additional indications are coming"
X Link @crashkolnikov 2025-08-26T13:47Z XXX followers, XXX engagements
"The Rolls of Rolls-Royce talking about BEVs in 1900: They are perfectly noiseless and clean. There is no smell or vibration and they should become very useful for town use when fixed charging stations can be arranged. But for country use I do not anticipate they will be very serviceable - at least for many years to come"
X Link @crashkolnikov 2025-10-13T11:12Z XXX followers, XXX engagements
"Looks like DB-OTO could be the leading contender for the first "not invented here" approval at $REGN. The other is cemdisiran but it's filing later without FTD. DB-OTO could be approval no. XX or XX depending whether garetosmab gets there first"
X Link @crashkolnikov 2025-10-13T14:51Z XXX followers, 1065 engagements
"DB-OTO awarded National Priority Voucher meaning decision within 1-2 months of filing. Having only entered trials in mid-23 it could be on the market XXX years later if approved What else has moved that fast outside Operation Warp Speed $REGN"
X Link @crashkolnikov 2025-10-17T09:09Z XXX followers, XXX engagements
"Were hearing the company may make it available either at an extremely low price or for free which of course is part of a national priority to make drugs more affordable so we would love that Sounds like $REGN might not be planning to make any money on DB-OTO. But as I point out above there's a lot more coming from them in this field - next up is GJB2 which is much less rare"
X Link @crashkolnikov 2025-10-17T09:16Z XXX followers, XXX engagements
"@MetacriticCap @amir Like Intel handed the Apple business to TSMC Microsoft hands the OpenAI business to Oracle"
X Link @crashkolnikov 2025-10-17T20:48Z XXX followers, XX engagements